Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 135.15M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -76.95M | Forward P/E | -2.29 | EPS next Y | - | 50D Avg Chg | -29.00% |
| Sales | 673k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -19.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -65.00% |
| Recommedations | 2.30 | Quick Ratio | 2.96 | Shares Outstanding | 132.64M | 52W Low Chg | 129.00% |
| Insider Own | 11.58% | ROA | -41.47% | Shares Float | 120.38M | Beta | 1.03 |
| Inst Own | 26.49% | ROE | -1,103.79% | Shares Shorted/Prior | 9.98M/8.86M | Price | 1.28 |
| Gross Margin | 6.98% | Profit Margin | - | Avg. Volume | 2,351,438 | Target Price | 4.00 |
| Oper. Margin | -2,680.24% | Earnings Date | - | Volume | 1,882,621 | Change | -8.57% |
About Gamida Cell Ltd.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
Gamida Cell Ltd. News